Thin Filament Interaction and Ca 2+ -Desensitization Effect of the C-Terminal End Peptide of Cardiac Troponin T Where Loss of Function Mutations Cause Hypertrophic Cardiomyopathy

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Troponin T (TnT) is the tropomyosin (Tm)-binding subunit of troponin with a central role in regulating cardiac muscle contractility. The recently identified Tm-binding site 3 in the highly conserved C-terminal end segment of TnT has a troponin I (TnI)-like inhibitory function. Conformational modulation by proteolytic removal of the N-terminal variable region of cardiac TnT (cTnT-ND) in adaptation to inotropy-afterload mismatch enhances the function of Tm-binding site 3 to adjust ventricular contractile kinetics and sustain stroke volume. Mutations in this segment of cTnT cause overactivation of cardiac muscle and hypertrophic cardiomyopathy (HCM).

Methods

The C-terminal end 14 amino acid peptide of cTnT (cTnT-C14) was analyzed for interactions with Tm, F-actin, and F-actin–Tm thin filament using localized surface plasmon resonance (LSPR). Wild-type and HCM mutant cTnT-C14 peptides were used to treat skinned cardiac muscle strips from wild-type and cTnT-ND transgenic mice to assess the effect on Ca²⁺- activation of contraction.

Results

cTnT-C14 peptide showed saturable binding to Tm and F-actin in LSPR with physiological affinity, which is significantly impaired by HCM mutation R278C, K280N or R286C. Treatment of wild-type mouse cardiac muscle strips with cTnT-C14 peptide produced a Ca 2+ - desensitization effect on myofilament activation, which was not seen with cTnT-ND mouse cardiac muscle strips implicating a prior utilization of the same mechanism. The HCM mutant peptides lost this function.

Conclusions

The findings demonstrate the function of the cTnT C-terminal end segment underlying the pathophysiology of the HCM mutations. Its preserved functionality in the form of free peptide presents a drug candidate for the treatment of heart failure.

Article activity feed